ArticleIrish journal of medical science2026
IHC analysis of estrogen receptor (ER) and progesterone receptor (PR) expression in endometrial carcinomas.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEndometrial carcinoma is one of the most common gynecological malignancies in developed and developing countries and its morbidity and mortality is rising yearly. Various factors including Age, FIGO stage, Tumor grade, Histological type, Lympho-vascular invasion, Biomarkers like ER, PR, PTEN and P53 play a major role in predicting prognosis of endometrial carcinomas.
aimsTo study the expression of ER and PR among endometrial carcinomas. MATERIALS AND
methodsThis study included 22 cases of hysterectomy which were histologically confirmed as endometrial carcinomas. After histopathological confirmation, paraffin blocks were selected for immunohistochemical evaluation of Estrogen and Progesterone receptor expression. Results of immunohistochemistry were correlated with various clinicopathological parameters. Statistical analysis was done with SPSS - version 24.
resultsAmong 22 cases, 72.7% were postmenopausal with mean age of 54.54 years. Histologically 72.7% were endometrioid type, with 27.3%, 36.4% and 36.4% cases showing features of Grade I, II and III respectively. 27.3%, 50% and 22.7% cases were in FIGO Stage I, II and III respectively with 22.7% cases showing LVI. 68.2% and 59.1% cases were positive for Estrogen and Progesterone receptor. Among endometrioid type, 87.5% cases were ER positive and 75% cases were PR positive. Among FIGO Stage I tumours, 100% cases were ER and PR positive.
conclusionsEstrogen and Progesterone receptor expression in endometrial carcinomas play a vital role in predicting prognosis. Hence a greater number of similar studies is recommended.
Indexed as
Identifiers
41528677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.